1492 Capital Initiates Stake in Cabot Corporation Amid Cyclical Turnaround Play

1492 Capital Management disclosed a new investment in Cabot Corporation (NYSE: CBT) during the first quarter, acquiring 48,057 shares. The transaction is estimated at $3.49 million, representing approximately 1.38% of the fund's total assets under management at the end of the quarter. The investment enters a period of stagnation for CBT, which has remained largely flat over the past year while the S&P 500 surged by roughly 35%. The fund's entry suggests a contrarian view that the stock's downside is limited and that market expectations have been sufficiently reset. Cabot's first-quarter financial performance was mixed, reporting revenue of $849 million and net income of $73 million. Adjusted earnings per share (EPS) fell 13% year-over-year to $1.53. This decline was primarily driven by the Reinforcement Materials segment, where EBIT dropped 22% to $102 million due to lower volumes. However, the company showed resilience in other areas. The Performance Chemicals segment saw a 7% increase in EBIT to $48 million, bolstered by demand for battery materials. Furthermore, Cabot maintains a healthy balance sheet with a net debt to EBITDA ratio of 1.2x and generated $126 million in operating cash flow. With $76 million returned to shareholders via dividends and buybacks, the company appears to be positioning itself for a cyclical recovery. The investment by 1492 Capital highlights a strategic bet on earnings stabilization within the specialty chemicals sector.